

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10729,499
Filing Date	December 5, 2003
First Named Inventor	Elfatih Elzein
Art Unit	
Examiner Name	
Attorney Docket Number	02-0175

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
EB		U.S. Patent No. 4,588,129	12-10-1985	Kluge et al.	4558	129	
		U.S. Patent No. 4,567,264	1-28-1986	Kluge et al.			
		U.S. Patent No. 4,766,125	8-23-1988	Van Daele et al.			
		U.S. Patent No. 5,472,707	12-5-1995	Samuels et al.			
		U.S. Patent No. 5,506,229	4-9-96	Dow et al.			
		U.S. Patent No. 5,906,988	5-0-1999	Dow			
		U.S. Patent No. 6,451,798	9-17-2002	Varkhedkar et al.			
		U.S. Patent No. 6,552,023	04-22-2003	Zablocki et al.			
		U.S. Patent No. 6,573,264	6-3-2003	Zablocki et al.			
		U.S. Patent No. 6,677,336	2-7-2002	Zablocki et al.	1013	04	
		U.S. Patent No. 6,638,970	10-28-2003	Elzein et al.			
		U.S. Patent No. 6,677,343	1-13-04	Blackburn et al.			
		US 2003/0181352	9-25-2003	Ibrahim et al.			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
EB		0 407 780	Jan, 1991	EP.			
		0 483 392	June, 1992	EP.			
		WO 01/62749	Aug, 2001	WO.			
		03 141258 A	June, 1991	JP (Abstract)			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
EB		MCCORMICK, et al. "Ranolazine: A Novel Metabolic Modulator for the Treatment of Angina", Gen Pharmac., vol. 30, No. 5, pp. 639-645, (1998).	
		SUZUKI T et al: "Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer.", Journal of Chemistry, vol. 40, no. 13, 1997, pages 2047-2052, XP000924067, the whole document, particularly page 2049, table 2, compound 5	
		ZACHAROWSKI K et al: "Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat." European Journal of Pharmacology, vol. 418, no. 1-2, April 20, 2001, pages 105-110, XP002215620, the whole document	
		LOPASCHUK G D: "Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism", The American Journal of Cardiology, vol. 82, no. 5A, September 3, 1997, pages 14K-17K, XP002215621, the whole document	

Examiner Signature	<i>F Bernhardt</i>	Date Considered	10/3/05
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.